CCRH-VC-Project- 06052018

Short Summary of CCRH-VC Project

Assessment of most frequently used rubrics and medicines in the

homeopathic treatment of acute conditions by Indian
Title
homoeopathic practitioners / researchers (CCRH) with the aid of
Vithoulkas Compass (VC)
Assessment of most frequently used rubrics and medicines in
Short Title
homoeopathic treatment of acute conditions
Methodology/Design Prospective, Exploratory, Open label, Observational study

Study Duration 6 months

12-13 centres: Will be decided by Director General, CCRH after
Study Centre(s)
finalising the co-investigators of the study
1. The VC online software platform is used for gathering and
analyzing data that are used for analyzing and improving
homeopathic practice.
2. CCRH has a considerable footfall of patients reporting with
acute conditions in its 29 research centers all over India.
Researchers in these centers are already seeing
acute/infectious cases in OPD and treating them on an
individualized basis.
3. Presently, the clinical data of treating acute/ infectious
conditions in these centers is not being stored electronically.
This, in conjunction with the lack of using a homoeopathy
software that can record the rubrics used for prescription of a
drug and its resultant effect on the case, leads to a huge
amount of important clinical data remaining unanalyzed.
4. CCRH, thus, faces the challenge of data recording and
assessment of a range of these diseases reporting to the
OPDs.
Background 5. VC is a handy software for:
a. Easy recording of basic data of patients/diseases,
b. Aiding in choosing the right remedy and
c. Analyzing/ interpreting the recorded data for
i. assessing the most common rubrics and
homeopathic medicines used by prescribers
in acute conditions and
ii. studying the prescribing patterns of the
researchers in day-to-day acute illnesses.
VC will be offered to researchers shortlisted for the study.
Practitioners will use the program for analyzing and treating their
acute cases; the symptoms used in the remedy selection and
treatment outcome will be assessed by VC and can be provided to
the CCRH for further analysis in required data formats.
The use of VC has significant benefits:
1) A decision support expert system
2) Key data on remedy selection, prescription and outcome will be
stored in a central database on an ongoing basis.
To improve repertory and materia medica based on statistical
Goal analysis of real-time information provided by the end users – the
prescribers
1. Assessment of most frequently used rubrics for prescribing
Objectives homoeopathic medicines in acute conditions
2. Studying the prescribing patterns of the Indian homoeopathic
researchers (CCRH)

Patients and
Methods
Number of Subjects
Common Inclusion
Criteria
Exclusion criteria
Follow-up period
Study Product, Dose,
Route, Regimen
Is this already highly
standardized? or do
practitioners have the
option to deviate from this
posology if/as appropriate?
If the described posology is
already established as
'routine', this is OK, because
the aim is to assess routine
clinical practice.
If this posology is NOT
routine, there is a potential
conflict with the aim to
evaluate routine practice. In
the latter case, I recommend
to allow more freedom in
terms of posology
Duration of
administration
Outcome assessment
Statistical Analysis
CCRH-VC-Project- 06052018
Patients reporting to (Outdoor Patient Departments) OPDs of
shortlisted study sites of CCRH with presentation of an acute
illness (not serious in nature) will be enrolled after obtaining their
consent.
The first consultation will mandatorily mention in Case notes:
The reporting day is the ___ (e.g. 3rd) day of catching
infection.
1000
1. Any acute condition not clinically serious* in nature
* See Point no. 2 of Exclusion criteria
1. Having undergone antibiotic treatment within 7 days prior to
enrolment in the study
2. Indications for referral to a specialist, like haemoptisis,
aspiration of a foreign body, heart attack, intestinal obstruction
etc.
3. Patients known to be suffering from serious hypertension
4. Patients who abused stimulants or had an illness that make
the practical participation in the study difficult.
5. Other ongoing treatment which is likely to interfere in the
course of this treatment.
6. Pregnant and lactating mothers
7-10 days, with at least one follow up in this period (more follow
ups are preferred for better assessment)
Study Product: Preference to be given to the Drugs enlisted in the
Essential Drugs List (EDL) (File attached)
Dose: Each dose of indicated medicine will consist of four globules
in sugar of milk (size no. 30); the potency will be increased in the
ascending order (if needed); and repeated as mentioned below:
• 6C: Not to be repeated >4 doses a day
• 30: Not to be repeated >2 doses a day
• 200: Not to be repeated >1 dose a day
• 1M & above: Once weekly (or as per need)
Route: Oral
Regimen: As followed in day to day routine; or as nature of illness
demands (E.g: Rest in case of fever etc.)
Preferably not more than 7-10 days; longer if case so demands
(with justification in case notes in latter case)
In case of complete resolution of the symptoms, the doctor should
ask as what day this was the case and report this in the case
notes.
To be undertaken in consultation with the VC Team. The onset
days and symptom resolution days (if applicable) will be entered
manually into an appropriate software package, with a view to
enabling the duration of the acute disease/episode for each
patient.